Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + Bevacizumab + Chemo + SBRT in EGFR-mutant NSCLC
NCT04517526Phase 2Unknown
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Nov 2020
- Primary completion
- Nov 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Fudan University Shanghai Cancer Center. Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04517526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04517526.